All Type of News
3.68 pills prescribed in 2012
Patients were prescribed with an average of 3.68 pills per hospital visit during the latter half of last year, compared to 4.15 pills in 2002 and 12.37 percent of hospitals prescribed more than six pills per visit dur...
Dong-A’s novel antibacterial agent receives positive results from Phase 3 clinical trial in severe s
Trius Therapeutics, Inc. on March 25 announced top-line results from its ESTABLISH 2 Phase 3 clinical trial of tedizolid phosphate (DA-7218) for the treatment of acute bacterial skin and skin structure infections (ABS...
Simponi, Enbrel set to fuel competition in rheumatism drug market
New brand Simponi (golimumab) and Enbrel (etanercept 50 mg) prefilled syringe are expected to rev up the domestic rheumatism drug market, which is valued at 85 billion won.
So far, three products, such as Janssen’s...
Who will become vice KFDA chief?
There is considerable interest over the next vice chief of the Korea Food and Drug Administration as the National Assembly passed President Park Geun-hye’s government reorganization bill last Friday bringing to an end...
Korea Pharm 2013 to open
Domestic pharmaceutical firms and foreign buyers will gather in Korea in May for an international meeting on pharmaceutical ingredients.
The Korea Pharm 2013 (Korea International Pharmaceutical Ingredient Exhibitio...
95.7% of doctors back additional treatment fee on Saturday
The great majority of practitioners agree to additional treatment charges on Saturdays which should be covered by national health insurance, a survey showed.
According to the survey of 1,058 practitioners conducted...
Daewoong Pharmaceutical names Chung J.G new vice presidentDaewoong Pharmaceutical promoted its OTC business division head Chung Jong-geun to lead its holding company Daewoong in the group’s latest executive reshuffle Monday.
Along w...
|
Government step up crackdown on rebate practices in medical industry
A heavier punishments over kickbacks, or rebates will be imposed starting April in a move aimed at enhancing overall transparency in the medical industry.
Under the revised guideline, the sales ban period of drugs ...
Pharmaceutical firms sitting on huge cash pile
Korean drug makers remain reluctant to invest. Instead, they are choosing to hold record amounts of cash reserves against the continued uncertain economic outlook and government’s drug related policies, which analysts...
Drug makers face bumpy road
Korea’s drug companies are facing a bumpy road ahead as a consequence of the government’s push to slash drug prices last April.
“The future growth of the domestic pharmaceutical industry is unclear because of drama...
